[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05918458":3,"trial-entities:NCT05918458":81,"trial-summary:NCT05918458":84},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":15,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":26,"secondary_outcomes":33,"sex":34,"minimum_age":35,"maximum_age":15,"healthy_volunteers":36,"eligibility_criteria":37,"std_ages":47,"locations":50,"central_contacts":60,"overall_officials":66,"references":69,"see_also_links":80},"NCT05918458","82814554","Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension","Pulmonary Hypertension Clinical Trials: What Are Prevailing Patient Experiences in Pulmonary Hypertension Studies","UNKNOWN","2026-07","2023-06","2023-06-26","2024-07","Power Life Sciences Inc.","INDUSTRY",null,"Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.\n\nThis study will admit a wide range of data on the clinical trial experience of pulmonary hypertension patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.\n\nIt will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future pulmonary hypertension patients.",[18],"Pulmonary Hypertension",[18],"OBSERVATIONAL",[],{"count":23,"type":24},500,"ESTIMATED",[],[27,30],{"measure":28,"timeFrame":29},"Number of patients who decide to enroll in a pulmonary hypertension clinical research","3 months",{"measure":31,"timeFrame":32},"Rate of patients who remain in pulmonary hypertension clinical research to trial completion","12 months",[],"ALL","18 Years",false,{"inclusion":38,"exclusion":42,"raw_text":46},[39,40,41],"Aged ≥ 18 years old","Able to comprehend the investigational nature of the protocol and provide informed consent","Diagnosis of pulmonary hypertension",[43,44,45],"No diagnosis of pulmonary hypertension confirmed","Inability to perform regular electronic reporting","Patient does not understand, sign, and return consent form","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n* Diagnosis of pulmonary hypertension\n\nExclusion Criteria:\n\n* No diagnosis of pulmonary hypertension confirmed\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",[48,49],"ADULT","OLDER_ADULT",[51],{"facility":52,"city":53,"state":54,"zip":55,"country":56,"geoPoint":57},"Power Life Sciences","San Francisco","California","94107","United States",{"lat":58,"lon":59},37.77493,-122.41942,[61],{"name":62,"role":63,"phone":64,"email":65},"Michael B Gill","CONTACT","415-900-4227","bask@withpower.com",[67],{"name":62,"affiliation":13,"role":68},"STUDY_DIRECTOR",[70,74,77],{"pmid":71,"type":72,"citation":73},"35926542","BACKGROUND","Jais X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, Chaouat A, Cottin V, De Groote P, Favrolt N, Horeau-Langlard D, Magro P, Savale L, Prevot G, Renard S, Sitbon O, Parent F, Tresorier R, Tromeur C, Piedvache C, Grimaldi L, Fadel E, Montani D, Humbert M, Simonneau G. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022 Oct;10(10):961-971. doi: 10.1016\u002FS2213-2600(22)00214-4. Epub 2022 Aug 1.",{"pmid":75,"type":72,"citation":76},"28025931","Divers C, Platt D, Wang E, Lin J, Lingohr-Smith M, Mathai SC. A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States. J Manag Care Spec Pharm. 2017 Jan;23(1):92-104. doi: 10.18553\u002Fjmcp.2017.23.1.92.",{"pmid":78,"type":72,"citation":79},"32657833","Harder EM, Waxman AB. Clinical trials in group 3 pulmonary hypertension. Curr Opin Pulm Med. 2020 Sep;26(5):391-396. doi: 10.1097\u002FMCP.0000000000000694.",[],{"nct_id":4,"conditions":82,"biomarkers":83},[18],[],{"nct_id":4,"found":85,"summary":86,"prompt_version":96},true,{"design":87,"status":88,"heading":89,"summary":90,"follow_up":91,"word_count":92,"commitments":93,"compensation":94,"drugs_mentioned":95},"This is an observational study aiming to enroll 500 participants. It is not testing any specific intervention or drug.","completed","Understanding Clinical Trial Experiences for Pulmonary Hypertension Patients","This study is looking to understand why some people with pulmonary hypertension (high blood pressure in the arteries of the lungs) join or finish clinical trials, while others don't. It's an observational study, meaning you won't receive any new treatments. Instead, researchers will gather information about your experiences with clinical trials. They want to see what factors might make it easier or harder for different groups of people to participate. The goal is to learn how to make future clinical trials better for patients with pulmonary hypertension. They hope to enroll 500 participants. To be eligible, you must be at least 18 years old, have a confirmed diagnosis of pulmonary hypertension, and be able to understand and sign the consent form.","The study will track how many patients enroll in research at 3 months and how many remain in research to completion at 12 months.",121,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]